# WuXi AppTec Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wuxi-apptec-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.wuxiapptec.com
- Total disclosed funding: $76M
- Latest round: Series C (Feb 1, 2007)
- Investors on record: 4

## About

Based in China, WuXi AppTec Co., Ltd. is a new drug developer whose services cover chemical drug research and development and production, biological research, preclinical testing and clinical trial development, cell and gene therapy research and development and testing, etc.

Established in 2000 and based in Shanghai, China, WuXi AppTec Groupis a pharmaceutical R&D service provider, focusing on new drug R&D and medical device R&D services. It has branch offices in South Korea, Japan and Singapore and has acquired EcoVadis Silver Certification. The company was listed on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange. The CEO, Li Ge, graduated from Columbia University in the United States with a Ph.D. in organic chemistry. The company has participated in new drug R&D projects with more than 4,400 partners from more than 30 countries. In December 2024, Altaris agreed to acquire WuXi AppTec Group's Advanced Therapies Unit. Financial terms were not disclosed. Upon completion, the firm will be rebranded as Advanced Therapies and headquartered in the United States.

WuXi AppTec Group is mainly engaged in small molecule new drug process research and development and production, chemical services and biological analysis services. The company has a CRDMO platform for small molecule drugs, oligonucleotide drugs and peptide drugs. The group also provides drug testing and clinical research services covering Phase I to Phase IV.

The company generates revenue by providing small molecule new drug process research and development and production, chemical services and biological analysis services.

## Funding rounds

- Series C, Feb 1, 2007, $55M — General Atlantic, Eight Roads Ventures
- Series B, Jun 1, 2006, $19M — UOB Venture Management, Eight Roads Ventures, TDGC
- Series A, Jul 1, 2005, $2.2M — Eight Roads Ventures

## Investors

- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A, Series B, Series C
- UOB Venture Management (https://capitalatlas.ai/funds/uob-venture-management) — Series B
- TDGC (https://capitalatlas.ai/funds/tdgc) — Series B
- General Atlantic (https://capitalatlas.ai/funds/general-atlantic) — Series C